Scott Curtis

Scott Curtis is the current Chief Operating Officer at Antibe Therapeutics. Prior to this, they were a Teacher Assistant (TA) at the University of Toronto from September 2013 to April 2014, in the Engineering Economics & Entrepreneurship program. From April 2012 to July 2013, they worked as an Associate in Investment Banking at Beacon Securities Ltd. And from May 2009 to March 2012, they worked as an Analyst in Healthcare Investment Banking at Bloom Burton & Co.

At Antibe Therapeutics, Scott is responsible for the company’s overall operations and performance. This includes leading and managing the company’s day-to-day activities, as well as developing and implementing long-term strategies. Prior to joining Antibe Therapeutics, Scott gained extensive experience in investment banking, transaction support, financial analysis and due diligence. Scott has also worked on various marketing and design projects for transaction purposes.

Scott holds a Bachelor of Commerce from the University of Toronto.

Scott Curtis has a Bachelor of Computing (Honours) from Queen's University, a Master of Engineering (MEng) from the University of Toronto, and a certification from the Canadian Securities Institute (CSI) in the Canadian Securities Course. Scott also has a certification from the CFA Institute as a Chartered Financial Analyst (CFA) charterholder and a certification from the University of Toronto in Entrepreneurship, Leadership, Innovation and Technology in Engineering (ELITE) Certificate.

They are on a team with Joseph Stauffer - Chief Medical Officer, Alain Wilson - Chief Financial Officer, and John L. Wallace - Founder, Chief Scientific Officer & Director. Scott Curtis reports to Dan Legault, Chief Executive Officer & Director.